Login to Your Account

Clinic Roundup

Friday, May 4, 2012

• FibroGen Inc., of San Francisco, said it expanded an ongoing Phase II study of GF-3019, a human monoclonal antibody against connective tissue growth factor, in patients with idiopathic pulmonary fibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription